PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for May 3, 2001 Subscribe to this News Feed    
 

New Product Offers Dramatic Effects to Heart Attack Sufferers

A natural, dietary supplement has been clinically shown to reduce the occurence of heart attacks in people at risk. The product also reduces some of the common side effects associated with coronary artery disease.

(Portola Hills, CA) Neopharmica, a California corporation has introduced a dietary supplement into the United States that purports to significantly reduce the chances of heart attack in known risk groups. This product, known as HeartHealth, is the subject of several clinical studies and is currently dispensed in over 130 hospitals in Asia. It not only has been shown to reduce risk of heart attack but also can significantly relieve chest pain, palpitations, dizziness, ringing in the ears and shortness of breath in patients with atherosclerosis of the heart. Some 60% of patients have been able to reduce or discontinue their heart medication. About 87% have obtained a generally effective improvement on their EKG profile.

Dr. Stephen Paul, President of Neopharmica and a 26 year veteran of the industry describes what other companies are doing. He explains, Ever notice what some vitamin ads are saying? They say, their product will: lower cholesterol, increase HDL levels, block fat absorption, improve lipid metabolism, lower homocysteine levels, improve blood circulation, etc. But, what does this all really mean? Will these vitamins make you live longer? Will you feel healthier? Can you reduce or eliminate some of the medicines you are taking? The fundamental issue then is not how vitamins can regulate or change biochemical events in your body. The real bottom line is whether they actually will make you live longer by reducing your chances of first time or recurrent heart attacks. HeartHealth is the first dietary supplement of its kind that has been clinically documented to be effective in risk reduction of heart attack."

Neopharmica is currently negotiating contracts with several firms, for the wholesale distribution of this product.

###

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Stephen Paul
Neopharmica
949.589.3646
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.